Preclinical and clinical development of DNA vaccines for prostate cancer.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Urologic oncology

• Publication date

  2016-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.urolonc.2013.09.014PMID 24332642PMCID PMC4053490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Vaccine.

  2017cited by this paper
• Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).

  2013cited by this paper
• Long-term immune responses elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with nonmetastatic castrate-resistant prostate cancer.

  2013cited by this paper
• Licensed DNA Vaccines against Infectious Hematopoietic Necrosis Virus (IHNV).

  2013cited by this paper
• A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results.

  2013cited by this paper
• The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer

  2013cited by this paper
• DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time

  2012influential reference
• Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response

  2012cited by this paper
• A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors

  2011cited by this paper
• Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.

  2011cited by this paper
• A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients.

  2011cited by this paper
• Vaccines Targeting the Cancer-testis Antigen SSX-2 Elicit HLA-A2 Epitope-specific Cytolytic T Cells

  2011cited by this paper
• Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research

  2011cited by this paper
• Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

  2010cited by this paper
• Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.

  2010cited by this paper
• Prostate Cancer Patients Treated with Androgen Deprivation Therapy Develop Persistent Changes in Adaptive Immune Responses

  2010cited by this paper
• Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

  2010cited by this paper
• DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T-cell Responses in Patients With Recurrent Prostate Cancer

  2010cited by this paper
• Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.

  2010cited by this paper
• In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010influential reference
• Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection

  2010cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010influential reference
• Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.

  2009influential reference
• The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

  2009cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.

  2009cited by this paper
• Skin Electroporation: Effects on Transgene Expression, DNA Persistence and Local Tissue Environment

  2009cited by this paper
• NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells

  2009cited by this paper
• Immune response to vaccination with DNA-hsp65 in a phase I clinical trial with head and neck cancer patients

  2009cited by this paper
• STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity

  2009cited by this paper
• TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines

  2008cited by this paper
• Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma

  2008cited by this paper
• Twelve immunotherapy drugs that could cure cancers.

  2008cited by this paper
• Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.

  2007cited by this paper
• A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients

  2007influential reference
• Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.

  2007cited by this paper
• Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells

  2007influential reference
• In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.

  2007cited by this paper
• Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.

  2007cited by this paper
• Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor1

  2007cited by this paper
• A xenogeneic PSMA DNA vaccine for patients (pts) with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)—A phase I trial of proof of principle

  2007cited by this paper
• Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.

  2006cited by this paper
• Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).

  2006cited by this paper
• Induction of PSA‐specific CTLs and anti‐tumor immunity by a genetic prostate cancer vaccine

  2005cited by this paper
• Phase I Study of a Plasmid DNA Vaccine Encoding MART-1 in Patients with Resected Melanoma at Risk for Relapse

  2005cited by this paper
• Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

  2005cited by this paper
• Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization

  2005cited by this paper
• Immune Monitoring in a Phase 1 Trial of a PSA DNA Vaccine in Patients with Hormone-Refractory Prostate Cancer

  2005influential reference
• A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer

  2004influential reference
• West Nile virus vaccines

  2004cited by this paper
• DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response.

  2003cited by this paper
• Inability to Immunize Patients with Metastatic Melanoma Using Plasmid DNA Encoding the gp100 Melanoma-Melanocyte Antigen

  2003cited by this paper
• Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma

  2003cited by this paper
• DNA vaccines: an active immunization strategy for prostate cancer.

  2003influential reference
• Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.

  2002cited by this paper
• Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.

  2002cited by this paper
• Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.

  2002influential reference
• CpG motifs in bacterial DNA and their immune effects.

  2002cited by this paper
• Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial

  2000influential reference
• Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates

  1999cited by this paper
• Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes.

  1996cited by this paper

• Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults

  2025cites this paper
• Prostate Cancer Vaccines: Progress, Challenges, and Future Directions

  2025cites this paper
• Nanoparticle-mediated enhancement of DNA Vaccines: Revolutionizing immunization strategies.

  2025cites this paper
• Unlocking Immunity: Innovative prostate cancer vaccine strategies.

  2024cites this paper
• Development of Personalized Strategies for Precisely Battling Malignant Melanoma

  2024cites this paper
• Tumour adaptation to immune factors: old and new ideas for cancer immunotherapy.

  2023cites this paper
• pDNA and mRNA vaccines

  2022cites this paper
• Instigation of the epoch of nanovaccines in cancer immunotherapy.

  2022cites this paper
• Preclinical Safety and Biodistribution in Mice Following Single-Dose Intramuscular Inoculation of Tumor DNA Vaccine by Electroporation

  2022cites this paper
• Immunotherapy – A Novel Facet of Modern Therapeutics

  2021cites this paper
• Pharmacokinetics aspects of biotechnological products

  2021cites this paper
• Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?

  2020cites this paper
• Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma

  2020cites this paper
• Vaccines as Immunotherapy

  2020cites this paper
• Strategies in DNA vaccine for melanoma cancer

  2020cites this paper
• Antigen Cross-Presentation by Macrophages

  2020cites this paper
• Cancer immunotherapy through the prism of adaptation: Will Achilles catch the tortoise?

  2020cites this paper
• Current State of the Art in DNA Vaccine Delivery and Molecular Adjuvants: Bcl-xL Anti-Apoptotic Protein as a Molecular Adjuvant

  2019cites this paper
• Nanoparticle cancer vaccines: Design considerations and recent advances

  2019cites this paper
• Plasmid-Based DNA Vaccines

  2018cites this paper
• Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus

  2018cites this paper
• Efficient Delivery of Tyrosinase Related Protein-2 (TRP2) Peptides to Lymph Nodes using Serum-Derived Exosomes.

  2018cites this paper
• Characterization of rabies pDNA nanoparticulate vaccine in poloxamer 407 gel

  2018cites this paper
• Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review

  2017cites this paper
• Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells

  2017cites this paper
• The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities

  2017cites this paper
• Trial watch: DNA-based vaccines for oncological indications

  2017cites this paper
• DNA vaccines for prostate cancer.

  2017cites this paper
• A primer on tumour immunology and prostate cancer immunotherapy.

  2016cites this paper
• B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines

  2016cites this paper
• Imaging Functional Nucleic Acid Delivery to Skin.

  2016cites this paper
• Bioreconhecimento de DNA minicircular por derivados de aminoácidos imobilizados em suportes monolíticos

  2016cites this paper
• Biochemistry - Knowledge to Practical Applications - Examples

  2016cites this paper
• Developing strategies to increase plasmid DNA production in Escherichia coli DH5α using batch culture.

  2016cites this paper
• Mannosylated protamine as a novel DNA vaccine carrier for effective induction of anti-tumor immune responses.

  2016cites this paper
• Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses

  2016cites this paper
• ประโยชน์ของพันธุวิศวกรรมในทางการแพทย์ (Applications of genetic engineering in medicine)

  2015cites this paper
• Biosynthesis of therapeutic DNA plasmid using agri-food subproducts media

  2015cites this paper
• Trial watch: Naked and vectored DNA-based anticancer vaccines

  2015cites this paper
• PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope–Modified DNA Vaccine Immunization

  2015cites this paper
• DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.

  2014cites this paper
• Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer

  2014cites this paper
• Medical Hypotheses

  year unknowncites this paper